How Will Artificial Intelligence Shape the Future of Decision-Making in Congenital Heart Disease?

Alice Pozza,Luca Zanella,Biagio Castaldi,Giovanni Di Salvo

DOI: https://doi.org/10.3390/jcm13102996

IF: 3.9

2024-05-21

Journal of Clinical Medicine

Abstract:Improvements in medical technology have significantly changed the management of congenital heart disease (CHD), offering novel tools to predict outcomes and personalize follow-up care. By using sophisticated imaging modalities, computational models and machine learning algorithms, clinicians can experiment with unprecedented insights into the complex anatomy and physiology of CHD. These tools enable early identification of high-risk patients, thus allowing timely, tailored interventions and improved outcomes. Additionally, the integration of genetic testing offers valuable prognostic information, helping in risk stratification and treatment optimisation. The birth of telemedicine platforms and remote monitoring devices facilitates customised follow-up care, enhancing patient engagement and reducing healthcare disparities. Taking into consideration challenges and ethical issues, clinicians can make the most of the full potential of artificial intelligence (AI) to further refine prognostic models, personalize care and improve long-term outcomes for patients with CHD. This narrative review aims to provide a comprehensive illustration of how AI has been implemented as a new technological method for enhancing the management of CHD.

medicine, general & internal

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore how artificial intelligence (AI) shapes the future decision - making in congenital heart disease (CHD). Specifically, the paper focuses on the following aspects:

1. **Improving diagnostic and monitoring capabilities**: By using advanced imaging techniques and deep - learning (DL) algorithms, AI can automatically detect and classify abnormalities in cardiac images, helping clinicians assess the severity of the disease and plan interventions. For example, AI technology can be used to accurately identify cardiac anatomical landmarks, assisting in early diagnosis and disease monitoring.

2. **Personalized treatment strategies**: AI promotes personalized treatment strategies for each patient's unique cardiac anatomy through automated image segmentation, feature extraction, and 3D reconstruction. This helps to detect potential problems earlier and provide more personalized treatment plans for patients.

3. **Clinical decision support**: The application of AI in clinical decision support systems (CDSS) can help pediatric cardiologists provide suggestions for diagnostic tests, treatment options, and follow - up plans based on the patient's CHD subtype, comorbidities, and risk factors. These systems improve the accuracy of clinical decision - making and reduce the risk of misdiagnosis and inappropriate treatment.

4. **Prognosis prediction**: AI technologies such as machine learning (ML) and deep - learning (DL) are applied to large - scale data sets containing clinical, imaging, and genomic data to predict various outcomes, such as mortality, hospital readmission, disease progression, and response to treatment. These models can generate personalized risk assessments, helping doctors better predict patients' long - term prognoses.

5. **Genetics and multi - omics analysis**: AI performs well in analyzing large amounts of complex genomic and transcriptomic data and can identify genetic variations related to CHD susceptibility, severity, and treatment response. By integrating multi - omics data, AI can reveal the molecular characteristics of the disease or indicative markers of treatment response, thereby providing a basis for personalized medicine.

In conclusion, this paper aims to comprehensively demonstrate how AI serves as a new technological means to enhance CHD management, especially in applications such as diagnosis, personalized treatment, and prognosis prediction.